Literature DB >> 27920076

Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers.

Lori A Gordon1, Parag Kumar2, Kristina M Brooks1, Anela Kellogg1, Maryellen McManus1, Raul M Alfaro1, Khanh Nghiem1, Jomy M George1, Jay Lozier1, Scott R Penzak1, Colleen Hadigan1.   

Abstract

Entities:  

Keywords:  anticoagulants; antiretroviral; cobicistat; dabigatran; drug-drug interaction; pharmacodynamics; pharmacokinetics; thrombin time

Mesh：

Substances：

Year:  2016        PMID： 27920076      PMCID： PMC5145004          DOI： 10.1161/CIRCULATIONAHA.116.025257

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  5 in total

1.  HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug Disposition.

Authors:  Olena Kis; Sumathi Sankaran-Walters; M Tozammel Hoque; Sharon L Walmsley; Satya Dandekar; Reina Bendayan
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

2.  HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement.

Authors:  A A Saber; A Aboolian; R D LaRaja; H Baron; K Hanna
Journal:  Am Surg       Date:  2001-07       Impact factor: 0.688

3.  Novel oral anticoagulants and HIV: dabigatran use with antiretrovirals.

Authors:  Jacinta Perram; Joanne Joseph; Cameron Holloway
Journal:  BMJ Case Rep       Date:  2015-11-20

4.  Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.

Authors:  Catia Marzolini; Sara Gibbons; Saye Khoo; David Back
Journal:  J Antimicrob Chemother       Date:  2016-03-05       Impact factor: 5.790

5.  Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects.

Authors:  Sebastian Härtter; Regina Sennewald; Gerhard Nehmiz; Paul Reilly
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335
  5 in total
  6 in total

1.  Response to "Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation".

Authors:  Tony Antoniou; Muhammad Mamdani; David Juurlink
Journal:  CMAJ       Date:  2017-02-27       Impact factor: 8.262

Review 2.  Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs).

Authors:  Megan C Herink; Yan F Zhuo; Craig D Williams; Thomas G DeLoughery
Journal:  Drugs       Date:  2019-10       Impact factor: 9.546

3.  Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.

Authors:  Parag Kumar; Lori A Gordon; Kristina M Brooks; Jomy M George; Anela Kellogg; Maryellen McManus; Raul M Alfaro; Khanh Nghiem; Jay Lozier; Colleen Hadigan; Scott R Penzak
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran.

Authors:  Payal P Kakadiya; Patricia Pecora Fulco; Robert T Higginson
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

5.  Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs).

Authors:  Xiaokui Huo; Qiang Meng; Changyuan Wang; Yanna Zhu; Zhihao Liu; Xiaodong Ma; Xiaochi Ma; Jinyong Peng; Huijun Sun; Kexin Liu
Journal:  Acta Pharm Sin B       Date:  2019-02-18       Impact factor: 11.413

6.  Cobicistat: A case of mislabelled drug-drug interaction risk?

Authors:  David M Burger; Alexandra Calmy; Catia Marzolini
Journal:  Br J Clin Pharmacol       Date:  2020-03-06       Impact factor: 4.335
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.